Calcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Open Access
- 7 November 2024
- journal article
- case report
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (12) , luae209
Abstract
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases. Calcitriol (1,25-dihydroxyvitamin D)-mediated hypercalcemia is rare and typically associated with granulomatous conditions; however, other solid-organ etiologies have been reported. Here, we detail the case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor (pNET) with hypercalcemia refractory to traditional bisphosphonate therapy in the setting of vastly elevated 1,25-dihydroxyvitamin D. Only after initiation of chemotherapy with capecitabine and temozolomide did his serum calcium consistently improve and 1,25-dihydroxyvitamin D begin to decrease. There are fewer than 5 reported cases of a pNET resulting in calcitriol-mediated hypercalcemia. Prompt initiation of treatment for the underlying condition can result in a significant improvement in serum calcium or 1,25-dihydroxyvitamin D. Multiple reports have also demonstrated success with high-dose steroid administration in patients with other solid-organ etiologies of calcitriol-mediated hypercalcemia, but this has not yet been reviewed in the pNET population.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (T32DK007245)
This publication has 13 references indexed in Scilit:
- Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in SarcomaAACE Clinical Case Reports, 2021
- Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosisEuropean Respiratory Review, 2020
- hypercalcaemia due to a calcitriol-producing neuroendocrine tumourJournal of Surgical Case Reports, 2019
- Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumorArchives of Endocrinology and Metabolism, 2017
- The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine TumorsThe Oncologist, 2016
- Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D2014
- Calcitriol-Mediated Hypercalcemia: Causes and Course in 101 PatientsThe Journal of Clinical Endocrinology & Metabolism, 2013
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experienceCancer Chemotherapy and Pharmacology, 2013
- Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by TemozolomideDigestive Diseases and Sciences, 2012
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010